Luteolin for Brain Fog

Luteolin appears in most brain fog protocols aimed at mast cell activation and neuroinflammation. The preclinical case is genuinely strong — it calms microglia and stabilises mast cells — but human evidence is limited to small studies of luteolin-containing combination formulas rather than luteolin alone.

Luteolin inhibits mast cell degranulation, reducing release of histamine, tryptase and IL-6 that can act on the brain, and it suppresses microglial activation and NF-kB-driven cytokine production. Since mast-cell and microglial signalling are the leading candidate mechanisms for inflammation-associated cognitive fogginess, the pharmacology maps neatly onto the symptom.

Most of the human work comes from Theoharides and colleagues, who developed luteolin-containing formulations and studied them in mast cell activation syndrome and autism. A small study in patients with mastocytosis reported improvement in "brain fog" symptoms with a luteolin-quercetin-rutin formulation, and open-label paediatric autism studies reported behavioural and communication gains. These were small, largely uncontrolled, used multi-ingredient products, and came predominantly from one research group with commercial involvement in the formulation — all reasons for caution rather than dismissal. Interest expanded during long-COVID research, where neuroinflammation hypotheses made luteolin a proposed candidate, but proposals and reviews are not trials, and the randomized evidence has not materialised. Bioavailability compounds the uncertainty: unformulated luteolin is poorly absorbed, so negative or weak results may reflect the delivery rather than the molecule. Verdict: insufficient evidence, with a mechanism worth watching.

People whose fog stems from poor sleep, untreated thyroid or iron deficiency, depression, or medication side effects will not respond to a mast cell stabiliser.